Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Read More Pharma Industry News RTW Biotech Opportunities joins $160.5m Series C of Obsidian Therapeutics RTW Biotech Opportunities Ltd, an investment company listed on the London Stock Exchange and specialized in the life… byPallavi MadhirajuApril 7, 2024